China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
89 hedge funds and large institutions have $1.68B invested in China Biologic Products Holdings, Inc. in 2020 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 18 closing their positions.
853% more call options, than puts
Call options by funds: $9.45M | Put options by funds: $992K
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
11% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 27
10% more capital invested
Capital invested by funds: $1.53B → $1.68B (+$150M)
2% more funds holding
Funds holding: 87 → 89 (+2)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$82.9M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$62M |
| 3 |
Millennium Management
New York
|
+$37.9M |
| 4 |
Capstone Investment Advisors
New York
|
+$30.9M |
| 5 |
PAM
PSquared Asset Management
Zurich,
Switzerland
|
+$23.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
-$133M |
| 2 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
-$39M |
| 3 |
MCP
Maso Capital Partners
Hong Kong
|
-$29.6M |
| 4 |
Renaissance Technologies
New York
|
-$25.1M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$20.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
AQR Capital Management
Greenwich,
Connecticut
| – | -$313K | -2,814 | Closed |
|
102
Jane Street
New York
| – | -$253K | -2,280 | Closed |
|
|
MIFH
103
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| – | -$249K | -2,242 | Closed |
|
|
PI
104
Putnam Investments
Boston,
Massachusetts
| – | -$213K | -1,919 | Closed |
|
105
Walleye Trading
New York
| – | -$26.7K | -230 | Closed |
|
|
AIM
106
Aigen Investment Management
New York
| – | -$4K | -37 | Closed |
|
|
CG
107
Cutler Group
San Francisco,
California
| – | -$1K | -9 | Closed |
|
CBPO Hedge Fund Activity: Q4 2020 in Review
89 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2020, worth a combined $1.68B — up 9.9% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CBPO positions and 18 closed out — a net gain of 3 holders — while 30 added to existing stakes and 27 trimmed.
The largest buyer was Pentwater Capital Management, adding an estimated $82.9M. The largest seller was York Capital Management Global Advisors, cutting an estimated $133M.
- 89 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2020, up from 87 in Q3 2020.
- Funds reported $1.68B of China Biologic Products Holdings, Inc. stock for Q4 2020, up 9.9% quarter-over-quarter.
- 21 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2020 and 18 closed out, a net change of +3 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q4 2020 was Pentwater Capital Management, an estimated $82.9M added.
- The largest China Biologic Products Holdings, Inc. seller in Q4 2020 was York Capital Management Global Advisors, an estimated $133M sold.
Based on aggregated 13F filings for Q4 2020.